文献速递类风湿关节炎

萨瑞鲁单抗治疗类风湿关节炎的真实世界52周日本全国研究

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).
PubMed 文献 · RMD Open · 2026-05-12

PROFILE-J 是日本全国、前瞻性、开放标签、非干预性观察研究,纳入1998例起始萨瑞鲁单抗的RA患者,其中567例单药、1431例联合csDMARDs。52周 retention 率为67.5%,CDAI从基线21.2降至第12周9.7,单药与联合治疗在第52周平均变化分别为-14.2和-14.9,PROs 均改善,TEAE 发生率44.6%,单药40.2%低于联合46.3%,无新安全信号。

要点

  • 萨瑞鲁单抗在真实世界中单药或联合csDMARDs均显示持续疗效至52周。
  • 67.9%患者为生物制剂初治,63.2%年龄≥65岁,提示起始人群以老年初治者为主。
  • TEAE发生率44.6%,单药40.2%略低于联合46.3%,未发现新安全信号。

核心结论

  • 萨瑞鲁单抗在RA真实临床实践中单药或联合csDMARDs均显示持续疗效和一致安全性,无新安全信号。

研究设计与样本

  • PROFILE-J为52周、前瞻性、非干预性、观察性、日本全国大型队列研究,纳入1998例起始萨瑞鲁单抗的成人RA患者,单药567例、联合1431例。

主要发现

  • 52周萨瑞鲁单抗 retention 率为67.5%。
  • 基线平均CDAI 21.2降至第12周9.7,第24周单药与联合平均变化分别为-13.6和-13.1,第52周分别为-14.2和-14.9。
  • PROs等其他指标在单药与联合组均显示相似改善。
  • 安全性人群中TEAE发生率44.6%,单药40.2%、联合46.3%。

临床怎么用

  • 真实世界数据支持萨瑞鲁单抗可作为单药或联合csDMARDs用于RA治疗,包括生物制剂初治的老年患者。

局限性

  • 研究为开放标签、非干预性观察设计,未设对照,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the patient characteristics and treatment patterns, effectiveness, safety and patient-reported outcomes (PROs) of sarilumab in routine clinical practice, used as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) in Japan. METHODS: Prospective Sarilumab (Prefilled Syringe/Pen) Observational Study-Japan (PROFILE-J) was a 52-week, prospective, non-interventional, observational study conducted across Japan. Adult patients with RA initiating sarilumab were enrolled. Effectiveness endpoints included Clinical Disease Activity Index (CDAI) scores, disease activity and PROs. Safety endpoints included treatment-emergent adverse events (TEAEs) and other clinically relevant safety outcomes. RESULTS: Among 1998 patients (monotherapy, n=567; combination, n=1431), the mean age was 66.6 years, with 63.2% aged ≥65 years and 67.9% naïve to biologic DMARDs. Sarilumab retention at week 52 was 67.5%. Effectiveness analysis population included 1715 patients (monotherapy, n=461; combination, n=1254). Baseline mean CDAI scores (21.2) decreased to low disease activity range (9.7) at week 12; mean changes from baseline were -13.6 and -13.1 at week 24 and -14.2 and -14.9 at week 52 for monotherapy and combination therapy respectively. Other measures, including PROs, showed similar improvements in both groups. In the safety population, TEAEs occurred in 44.6% of patients, with a slightly lower rate observed in monotherapy (40.2%) than in combination therapy (46.3%). CONCLUSIONS: This study described real-world treatment patterns of sarilumab, highlighting frequent initiation in biologic DMARD-naïve patients, particularly among older adults. Sarilumab demonstrated sustained effectiveness and a consistent safety profile with no new safety signals, supporting its use as monotherapy or combination therapy. TRIAL REGISTRATION NUMBER: jRCT1071190016.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tanaka Y, Hanami K, Miyazaki Y, et al. Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J). RMD Open. 2026. PMID: 42120177. doi:10.1136/rmdopen-2025-006446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。